Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Risperdal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Phase III pivotal study of a long-acting injectable depot version of risperidone shows "significantly greater improvement" on the Positive and Negative Symptom Scale for patients receiving the antipsychotic than those receiving placebo, Janssen's Marielle Eerdekens reports in a May 2 conference call. In the U.S. trial, which enrolled 400 schizophrenia patients, a decrease of more than 20% on the PANNS total score was seen in 47% and 48% of 25 and 50 mg risperidone patients, respectively, vs. 17% of placebo patients. The drop-out rate due to lack of efficacy was 22%, 16% and 12% for patients receiving 25, 50 and 75 mg risperidone, vs. 30% for placebo. The most frequently reported side effects were headache, agitation, insomnia and anxiety. The company plans to submit an NDA for the injectable agent shortly

You may also be interested in...

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts